Jesús Manuel
González Santiago
Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (12)
2024
-
Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance
American Journal of Gastroenterology, Vol. 119, Núm. 4, pp. 646-654
-
Impact of liver diseases and pharmacological interactions on the transportome involved in hepatic drug disposition
Biochemical Pharmacology, Vol. 228
-
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211
2023
2022
-
Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia
Hepatology, Vol. 76, Núm. 5, pp. 1259-1274
-
Location, morphology and invasiveness of lateral spreading tumors in the colorectum differ between two large cohorts from an eastern and western country
Gastroenterologia y Hepatologia, Vol. 45, Núm. 6, pp. 440-449
-
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study
Liver International, Vol. 42, Núm. 8, pp. 1891-1901
2021
-
Compound endoscopic morphological features for identifying non-pedunculated lesions ≥20 mm with intramucosal neoplasia
Cancers, Vol. 13, Núm. 21
-
Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics
Aging, Vol. 13, Núm. 19, pp. 23416-23434
2019
-
Accuracy of the Narrow-Band Imaging International Colorectal Endoscopic Classification System in Identification of Deep Invasion in Colorectal Polyps
Gastroenterology, Vol. 156, Núm. 1, pp. 75-87
-
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
Journal of Hepatology, Vol. 71, Núm. 4, pp. 666-672
2017
-
Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection
International Journal of Clinical Practice, Vol. 71, Núm. 9